Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v9-FR Version v2-FR
Language French French
Date Updated 2020-07-29 2020-04-07
Drug Identification Number 02018144 02018144
Brand name CYCLOMEN CYCLOMEN
Common or Proper name Cyclomen Cyclomen
Company Name SANOFI-AVENTIS CANADA INC SANOFI-AVENTIS CANADA INC
Ingredients DANAZOL DANAZOL
Strength(s) 50MG 50MG
Dosage form(s) CAPSULE CAPSULE
Route of administration ORAL ORAL ORAL ORAL
Packaging size 100 100
ATC code G03XA G03XA
ATC description OTHER SEX HORM. & MODULATORS OF THE GENITAL SYSTEM OTHER SEX HORM. & MODULATORS OF THE GENITAL SYSTEM
Reason for shortage Demand increase for the drug. Demand increase for the drug.
Anticipated start date 2020-04-30 2020-04-30
Actual start date
Estimated end date 2020-08-07 2020-07-15
Actual end date 2020-07-28
Shortage status Resolved Anticipated shortage
Company comments The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy. The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy.
Health Canada comments